Bristol-Myers Squibb BMY · NYSE
$59.11 -1.07% (-$0.64)
Summary
67 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 19 USD is left as net profit.
- It has raised its dividend 18 years in a row and pays out only 55% of profit.
- It earns 15 USD a year on every 100 USD of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue grew by only 1.4% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 13.2 USD for 1 USD of yearly profit. Over the last five years it was 18.3 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 2.5% a year over 5 years. Over the last 3 years it grew by 1.4% a year. For the next fiscal year analysts expect revenue to grow by 3.5%. Earnings per share grew by 5.4% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 30 USD
- Research and development 22 USD
- Sales and administration 20 USD
- Taxes and other 9.4 USD
- Net profit 19 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 19 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 4.21%
- Paid out of profit
- 55%
- Raised in a row
- 18 years
You receive $2.52 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
Neutral- Buy 19
- Hold 21
- Sell 2
Today's price within the analysts' price targets
The average target of $65.18 is 10% above today's price. 45% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Eliquis 30%
- Opdivo 21%
- Orencia 7.7%
- Revlimid 6.1%
- Yervoy 6.0%
- Other 29%
By region
- UNITED STATES 97%
- Other Region 3.2%
Eliquis brings in 30% of revenue. Yervoy grew fastest, by 9.4% a year.
Segments in detail